TerminatedPhase 4

Adult Growth Hormone Deficiency and Cardiovascular Risk

Stopped: poor enrollment

United States7 participantsStarted 2007-02

Plain-language summary

This protocol will assess the cardiovascular risk associated with growth hormone deficiency in adults. We will use multiple modalities to assess risk for heart attacks or strokes including blood work, ultrasound, MRI and endothelial cell biopsies in both patients who are growth hormone deficient and in patients with normal growth hormone secretion. We hypothesize that adults with growth hormone deficiency will have results suggestive of an increased risk for cardiovascular disease.

Who can participate

Age range19 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adults 19 years or older who have undergone transsphenoidal surgery for a clinically non-secreting pituitary adenoma Exclusion Criteria: * Currently taking growth hormone, radiation therapy in the past 5 years, changes in dose of other pituitary hormone replacement therapy in past 3 months, taking hydrocortisone (or its equivalent) at a dose of \> 30 mg/day, pregnant or nursing women

What they're measuring

C-reactive Protein (CRP) Levels

Timeframe: Day 1

Homocysteine Level

Timeframe: Day 1

Total Cholesterol Level

Timeframe: Day 1

Trial details

NCT IDNCT00720902

SponsorColumbia University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2010-03

Results submitted2017-02-02

View on ClinicalTrials.gov More Growth Hormone Deficiency trials